Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

FDA Greenlights DermaSensor: First AI Device for Detecting Skin Cancer

Jan 20, 2024 - techtimes.com
The Food and Drug Administration (FDA) has approved an AI-powered medical device developed by DermaSensor, designed to assist doctors in identifying common forms of skin cancer. The device uses AI-powered spectroscopy technology to evaluate suspicious lesions, providing real-time results based on an AI algorithm trained on data from over 4,000 benign and malignant lesions. The FDA has emphasized that the device is a supplementary diagnostic tool, not a screening device, and should be used in conjunction with clinically relevant information.

In other news, researchers at UC San Diego School of Medicine are using AI to suggest the best cancer therapies based on tumor gene mutation complexity. The AI identifies 90 crucial genes for treatment decisions, aiming to assist doctors in navigating the complex landscape of cancer mutations and treatment options. The FDA approval for DermaSensor's device comes with a stipulation for the company to conduct additional validation testing in patients from diverse demographic groups.

Key takeaways:

  • The FDA has approved DermaSensor's AI-powered medical device, the first of its kind designed to assist doctors in identifying common forms of skin cancer.
  • The device uses AI-powered spectroscopy technology to evaluate suspicious lesions, providing real-time results based on data from over 4,000 benign and malignant lesions.
  • DermaSensor screens moles for basal cell carcinoma, squamous cell carcinoma, and melanoma, offering a critical tool for early detection of skin cancer.
  • UC San Diego School of Medicine researchers are using AI to suggest the best cancer therapies based on tumor gene mutation complexity, identifying 90 crucial genes for treatment decisions.
View Full Article

Comments (0)

Be the first to comment!